Sonnet BioTherapeutics Holdings, Inc. (SONN)

USD 1.61

(-6.4%)

Market Cap (In USD)

4.12 Million

Revenue (In USD)

147.8 Thousand

Net Income (In USD)

-18.83 Million

Avg. Volume

135.49 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.57-18.72
PE
-
EPS
-
Beta Value
1.045
ISIN
US83548R3030
CUSIP
83548R105
CIK
1106838
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Pankaj Mohan Ph.D.
Employee Count
-
Website
https://www.sonnetbio.com
Ipo Date
2006-10-31
Details
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.